A genetic mutation seven times as common in blacks as in whites increases the odds that people taking a common HIV medicine will suffer side effects that lead them to halt the treatment. Because the mutation slows metabolism of the drug efavirenz, patients of either race who have the genetic trait might be better off receiving, from the start of therapy, only a low dose of efavirenz, says David W.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.